SLRX•benzinga•
Salarius And Decoy Announces Merger, Decoy To Hold 86% Post-Conversion; Lead Asset To File IND With FDA; Advancements In Broad-Acting Antiviral And Peptide Drug Conjugate; Data Expected From MDACC Trial
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga